title: Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock.
abstract: The therapeutic efficacy of protegrin peptide IB-367 was investigated in three rat models of septic shock: (i) rats injected intraperitoneally with 1mg Escherichia coli 0111:B4 lipopolysaccharide, (ii) rats given an intraperitoneal injection of 2 X 10(10) CFU of E. coli ATCC 25922, and (iii) rats in which intra-abdominal sepsis was induced via cecal ligation and puncture. All animals were randomized to receive parenterally isotonic sodium chloride solution, 1mg/kg of IB-367, 60mg/kg piperacillin and 1mg/kg of IB-367 plus 60mg/kg piperacillin. The peptide demonstrated lower level of antimicrobial activity than piperacillin, nevertheless it exhibited the dual properties of antimicrobial and antiendotoxin agent. Finally IB-367 and piperacillin association showed to be the most effective therapeutic approach.
authors.affiliation: Institute of Infectious Diseases and Public Health, Clinica delle Malattie Infettive, Università Politecnica delle Marche, c/o Ospedale Regionale, Via Conca, 60020 Torrette AN, Ancona, Italy. anconacmi@interfree.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Giacometti
authors.forename: Oscar
authors.initials: O
authors.lastname: Cirioni
authors.forename: Roberto
authors.initials: R
authors.lastname: Ghiselli
authors.forename: Federico
authors.initials: F
authors.lastname: Mocchegiani
authors.forename: Claudio
authors.initials: C
authors.lastname: Viticchi
authors.forename: Fiorenza
authors.initials: F
authors.lastname: Orlando
authors.forename: Giuseppina
authors.initials: G
authors.lastname: D'Amato
authors.forename: Maria Simona
authors.initials: MS
authors.lastname: Del Prete
authors.forename: Wojciech
authors.initials: W
authors.lastname: Kamysz
authors.forename: Jerzy
authors.initials: J
authors.lastname: łLukasiak
authors.forename: Vittorio
authors.initials: V
authors.lastname: Saba
authors.forename: Giorgio
authors.initials: G
authors.lastname: Scalise
mesh_terms: D000818:Animals; D023181:Antimicrobial Cationic Peptides; D002432:Cecum / Q000601:surgery; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy*; D008026:Ligation; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008826:Microbial Sensitivity Tests; D010455:Peptides; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D010878:Piperacillin / Q000008:administration & dosage* / Q000627:therapeutic use*; D011506:Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D011677:Punctures; D051381:Rats; D017208:Rats, Wistar; D012772:Shock, Septic / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology
chemical_list: D023181:Antimicrobial Cationic Peptides; D008070:Lipopolysaccharides; D010455:Peptides; D011506:Proteins; C119872:antimicrobial peptide IB-367; D010878:Piperacillin